Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
$53.94M
Mr. Simon J. Allen B.Sc., M.B.A., MBA
4.00
Lakeway, TX
May 07, 2021
-5.62
$-0.37
5.09
5.32
0.00%
-6.30
0.00
11.81
0.00
5.32
-155.90%
-122.97%
Similar stocks (5)
AnaptysBio, Inc.
ANAB
Acrivon Therapeutics, Inc. Common Stock
ACRV
PMV Pharmaceuticals, Inc.
PMVP
Aerovate Therapeutics, Inc.
AVTE
AN2 Therapeutics, Inc.
ANTX
ETF Exposure (6)
iShares Micro-Cap ETF
IWC
7.2e-4%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (5)
AnaptysBio, Inc.
ANAB
Acrivon Therapeutics, Inc. Common Stock
ACRV
PMV Pharmaceuticals, Inc.
PMVP
Aerovate Therapeutics, Inc.
AVTE
AN2 Therapeutics, Inc.
ANTX
ETF Exposure (6)
iShares Micro-Cap ETF
IWC
7.2e-4%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%